Literature DB >> 18179653

Is routine pre-anaesthetic haematological and biochemical screening justified in dogs?

Michaele Alef1, Ferdinand von Praun, Gerhard Oechtering.   

Abstract

OBJECTIVES: To determine if routine haematological and biochemical screening is of benefit in dogs requiring anaesthesia and to establish the most useful tests for pre-anaesthetic risk assessment. ANIMALS: One thousand five hundred and thirty-seven client-owned dogs undergoing surgery at the University of Leipzig between January 2003 and April 2004.
MATERIALS AND METHODS: After obtaining a standardized history and a physical examination, all dogs requiring anaesthesia were assigned to an ASA physical status group, their needs for pre-anaesthetic therapy determined and an anaesthetic protocol proposed. Haematological (haematocrit, red blood cell count, white blood cell count, platelet count and haemoglobin concentration) and serum biochemistry tests (plasma urea, creatinine, glucose, total protein, sodium and potassium concentration; serum alanine aminotransferase, alkaline phosphatase and lipase activity) were then performed in all animals. The results of these were then used to: 1) re-define each dog's ASA physical status; 2) determine any altered requirement for pre-anaesthetic therapy; 3) re-determine the suitability of the dog to undergo surgery; and 4) re-examine the suitability of the original proposed anaesthetic protocol.
RESULTS: The history and clinical examination in 1293 out of 1537 dogs (84.1%) revealed that haematological and biochemical tests would have been considered unnecessary under normal conditions. Of these, 63.9% were categorized as ASA 1, 28.5% as ASA 2, and 7.6% at higher risk. In some dogs, screening tests showed abnormal results: 16.7% of 1293 dogs had abnormal plasma urea levels, with 5.9% of values above the reference range. However, only 104 dogs (8%) would have been re-categorized at a higher physical status category had the laboratory results been available. Additional screening data indicated that surgery would have been postponed in 10 dogs (0.8%) additional pre-anaesthetic therapy would have been provided in 19 animals (1.5%) and the anaesthetic protocol altered in two dogs (0.2%).
CONCLUSION: The changes revealed by pre-operative screening were usually of little clinical relevance and did not prompt major changes to the anaesthetic technique. CLINICAL RELEVANCE: In dogs, pre-anaesthetic laboratory examination is unlikely to yield additional important information if no potential problems are identified in the history and on physical examination.

Entities:  

Mesh:

Year:  2008        PMID: 18179653     DOI: 10.1111/j.1467-2995.2007.00364.x

Source DB:  PubMed          Journal:  Vet Anaesth Analg        ISSN: 1467-2987            Impact factor:   1.648


  5 in total

1.  Ultrasonographic and laboratory screening in clinically normal mature golden retriever dogs.

Authors:  Jinelle A Webb; Gordon M Kirby; Stephanie G Nykamp; Meredith J Gauthier
Journal:  Can Vet J       Date:  2012-06       Impact factor: 1.008

2.  Effect of routine pre-anesthetic laboratory screening on pre-operative anesthesia-related decision-making in healthy dogs.

Authors:  Krista Mitchell; Michele Barletta; Jane Quandt; Molly Shepard; Stephanie Kleine; Erik Hofmeister
Journal:  Can Vet J       Date:  2018-07       Impact factor: 1.008

3.  Effect of screening abdominal ultrasound examination on the decision to pursue advanced diagnostic tests and treatment in dogs with neurologic disease.

Authors:  N M Tong; A L Zwingenberger; W H Blair; S L Taylor; R X Chen; B K Sturges
Journal:  J Vet Intern Med       Date:  2015-04-21       Impact factor: 3.333

4.  Effects of midazolam on cardiovascular responses and isoflurane requirement during elective ovariohysterectomy in dogs.

Authors:  Josephine Kropf; J M Lynne Hughes
Journal:  Ir Vet J       Date:  2018-12-17       Impact factor: 2.146

5.  Geriatric screening in first opinion practice - results from 45 dogs.

Authors:  M Davies
Journal:  J Small Anim Pract       Date:  2012-07-27       Impact factor: 1.522

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.